Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. Schilder RJ, et al. Among authors: sood ak. Gynecol Oncol. 2013 Apr;129(1):86-91. doi: 10.1016/j.ygyno.2013.01.006. Epub 2013 Jan 13. Gynecol Oncol. 2013. PMID: 23321064 Free PMC article. Clinical Trial.
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F. Sood A, et al. Eur Urol Oncol. 2024 Feb;7(1):27-43. doi: 10.1016/j.euo.2023.06.002. Epub 2023 Jul 8. Eur Urol Oncol. 2024. PMID: 37423774 Review.
The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort.
Finati M, Davis M, Stephens A, Chiarelli G, Cirulli GO, Morrison C, Affas R, Sood A, Buffi N, Lughezzani G, Briganti A, Montorsi F, Carrieri G, Rogers C, Vickers AJ, Abdollah F. Finati M, et al. Eur Urol Oncol. 2024 Jul 10:S2588-9311(24)00172-X. doi: 10.1016/j.euo.2024.06.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38991891
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.
Murray CE, Kornepati AVR, Ontiveros C, Liao Y, de la Peña Avalos B, Rogers CM, Liu Z, Deng Y, Bai H, Kari S, Padron AS, Boyd JT, Reyes R, Clark CA, Svatek RS, Li R, Hu Y, Wang M, Conejo-Garcia JR, Byers LA, Ramkumar K, Sood AK, Lee JM, Burd CE, Vadlamudi RK, Gupta HB, Zhao W, Dray E, Sung P, Curiel TJ. Murray CE, et al. Among authors: sood ak. Mol Cancer. 2024 Oct 30;23(1):242. doi: 10.1186/s12943-024-02147-z. Mol Cancer. 2024. PMID: 39478560
The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy.
Nitecki Wilke R, Liu J, Westin SN, Fellman BM, Sims TT, Pham M, Rangel K, Sey E, Rauh-Hain JA, Lu KH, Sood AK, Fleming ND. Nitecki Wilke R, et al. Among authors: sood ak. Int J Gynecol Cancer. 2024 Oct 16:ijgc-2024-005893. doi: 10.1136/ijgc-2024-005893. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39414313
TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors.
Brodsky AL, Flores Legarreta A, Fellman BM, Glassman D, How J, Vuttaradhi V, Sood AK, Ramondetta LM, Gershenson D, Hillman RT. Brodsky AL, et al. Among authors: sood ak. Int J Gynecol Cancer. 2024 Oct 12:ijgc-2024-005837. doi: 10.1136/ijgc-2024-005837. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39395821
1,157 results